Skip to main content

Table 1 Patients’ clinical characteristics according to tumor response pattern (n = 155)a

From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Total patients HPD (n = 26) SD/PR/CR (n = 129) P value
Age (year) 58.96 ± 10.2 65.19 ± 9.1 0.002
Gender, Female: Male 3:23 35:94 0.092
Smoking history (pack/y) 29.3 ± 19.6 24.41 ± 21.6 0.284
  < 20 5 51 0.049
  ≥ 20 21 78  
Histologic subtype    0.061
 Adenocarcinoma 14 93  
 Squamous cell carcinoma 11 34  
 Others 1 2  
Oncogenic driver mutations    
 Yes: No 8:18 16:113 0.018
EGFR mutation 5 7  
 ALK, ROS1, and others 3 9  
Number of metastatic sites    0.005
  < 3 17 113  
  ≥ 3 9 16  
Prior treatment lines before ICBs    0.139
  < 3 21 117  
  ≥ 3 5 12  
  1. Values are presented as mean ± standard deviation, ratio, or number
  2. aNon-evaluable group and non-HPD PD group were excluded
  3. ALK Anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, HPD hyperprogressive disease, Non-HPD PD non-HPD progressive disease, OS overall survival, PR/CR partial/complete response, SD stable disease